• CENTRE FOR COMMERCIALIZATION OF CANCER IMMUNOTHERAPY C3I



 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

Triumvira Immunologics Announces Strategic Relationship for GMP Manufacturing with Centre for Commercialisation of Cancer Immunotherapy

Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple cancers, today announced a strategic relationship with the Centre for Commercialisation of Cancer Immunotherapy (C3i), a catalyst for accelerating market access of breakthrough innovations to fight cancer. Under the terms of the agreement, C3i will deliver cell therapy products for Triumvira’s global Phase 1 and 2 clinical trials and has committed to underwrite an investment in the company.

C3i is supporting the development of a lymphoma registry, with HMR and Dr Isabelle Fleury

The Center for Commercialization of Cancer Immunotherapy (C3i) is proud to announce a partnership with Hôpital Maisonneuve-Rosemont (HMR) and Dr. Isabelle Fleury, Hematologist and Medical Oncologist at HMR, to support the development of a Lymphoma Registry.

 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

C3i’s Biomarker and Diagnostic unit now offers TCR-beta sequencing services

November 13th, 2017

The Center for Commercialization of Cancer Immunotherapy (C3i) is proud to announce the availability of T cell receptor-beta sequencing services in its Biomarker and Diagnostic unit.

 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

C3i participates to the challenge Cycle for a Cure!

September 30th, 2017

The 6th edition of the Bike Challenge for Cellular Therapy Research at the Maisonneuve-Rosemont Hospital will give you the opportunity to support scientific work that promotes healing.

 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

IRICoR and C3i Announce Partnership to Identify novel Tumor-Specific Antigens (TSAs)

April 4th, 2017

Novel Approach to Identifying TSAs based on a unique mass spectrometry approach discovered at IRIC combined with expertise in genomic sequencing and clinical validation from C3i

 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

Government of Canada invests in research commercialization

February 12th, 2016

$29 million investment in two commercialization centres will accelerate Canadians’ access to innovative cancer immunotherapies and natural products